FGF1ΔHBS delays the progression of diabetic nephropathy in late-stage type 2 diabetes mouse model by alleviating renal inflammation, fibrosis, and apoptosis

• Published in: Biochimica et biophysica acta. Molecular basis of disease 2022-08, Vol.1868 (8), p.166414-166414, Article 166414
• Main Authors: Lin, Qian, Chen, Oscar, Wise, John P., Shi, HongXue, Wintergerst, Kupper A., Cai, Lu, Tan, Yi
• Format: Article
• Language: English
• Subjects: Aged; Animals; Apoptosis; Diabetes Mellitus, Type 2 - complications; Diabetic Nephropathies - drug therapy; Diabetic Nephropathies - metabolism; Diabetic nephropathy; Disease Models, Animal; Female; FGF1ΔHBS; Fibroblast Growth Factor 1 - genetics; Fibroblast Growth Factor 1 - pharmacology; Fibroblast Growth Factor 1 - therapeutic use; Fibrosis; Humans; Inflammation; Inflammation - drug therapy; Inflammation - metabolism; Male; Mice; PPAR alpha; Type 2 diabetes
• ISSN: 0925-4439; 1879-260X
• DOI: 10.1016/j.bbadis.2022.166414

Elderly adults are at higher risk for developing diabetic complications including diabetic nephropathy (DN), contributing to excess morbidity and mortality in elderly individuals. A non-mitogenic variant of fibroblast growth factor 1 (FGF1ΔHBS) was demonstrated to prevent DN in an early-stage (2-month-old) type 2 diabetes (T2D) mouse model. The present study aimed to investigate the potential therapeutic effects of FGF1ΔHBS against the progression of renal dysfunction in a late-stage T2D mouse model with established DN. Nine-month-old db/db mice were administered FGF1ΔHBS every other day for 3 months. db/db mice at 12-month-old without FGF1ΔHBS treatment exhibited high blood glucose level and elevated urine albumin-to-creatinine ratio. FGF1ΔHBS treatment effectively reversed hyperglycemia, delayed the development of renal dysfunction, and reduced kidney size and weight. Furthermore, FGF1ΔHBS treatment significantly prevented the progression of renal morphologic impairment. FGF1ΔHBS treatment demonstrated anti-inflammatory and anti-fibrotic effects, with significantly decreased protein levels of key pro-inflammatory cytokines and pro-fibrotic factors in kidney. Moreover, FGF1ΔHBS treatment greatly decreased apoptosis of renal tubular cells, accompanied by significant downregulation of the proapoptotic protein and upregulation of the antiapoptotic protein and peroxisome proliferator-activated receptor α (PPARα) expression in kidney. Mechanistically, FGF1ΔHBS treatment directly protected mouse proximal tubule cells against palmitate-induced apoptosis, which was abolished by PPARα inhibition. In conclusion, this study demonstrated that FGF1ΔHBS delays the progression of renal dysfunction likely through activating PPARα to prevent renal tubule cell death in late-stage T2D, exhibiting a promising translational potential in treating DN in elderly T2D individuals by ameliorating renal inflammation, fibrosis and apoptosis. •A non-mitogenic variant FGF1ΔHBS delays the progression of renal dysfunction.•FGF1ΔHBS suppresses the renal inflammation, fibrosis and apoptosis.•PPARα inhibition abolishes FGF1ΔHBS protecting from apoptosis in renal tubular cells.